Retatrutide is an investigational medication that is still undergoing clinical trials. It has not been approved by the FDA, MHRA, or any other regulatory authority for use in humans as of June 2026. The information in this article is for educational and informational purposes only. It is not intended as medical advice, diagnosis, or treatment recommendation. Always consult a qualified healthcare professional before considering any medication or treatment. Self-administration or sourcing from unregulated channels can be dangerous and is strongly discouraged.
What is Retatrutide?
Retatrutide (also known as LY3437943) is an investigational once-weekly injectable medication being developed by Eli Lilly for the treatment of obesity and overweight with related health conditions. It belongs to a new class of medicines known as triple hormone receptor agonists.
Unlike earlier weight management medications that target one or two hormone pathways, retatrutide is designed to mimic the effects of three naturally occurring hormones in the body:
- Glucagon-like peptide-1 (GLP-1)
- Glucose-dependent insulinotropic polypeptide (GIP)
- Glucagon
This triple-action mechanism is what sets it apart from medications like semaglutide (Wegovy/Ozempic) and tirzepatide (Mounjaro/Zepbound). Researchers believe that activating all three receptors may lead to greater effects on appetite regulation, digestion, energy expenditure, and fat metabolism.
Retatrutide is currently in Phase 3 clinical trials. While early results have generated significant interest, it remains an experimental treatment.
How Does Retatrutide Work?
Retatrutide works by activating three key hormone receptors simultaneously:
- GLP-1 Receptor — Helps slow gastric emptying, reduces appetite, and supports better blood sugar control by stimulating insulin release when needed.
- GIP Receptor — Works alongside GLP-1 to further enhance insulin response and may help reduce food intake.
- Glucagon Receptor — Increases energy expenditure and promotes the breakdown of fat stores for energy rather than storage.
By targeting these three pathways at once, retatrutide aims to create a more comprehensive effect on body weight regulation compared to single or dual agonists. Clinical trials are evaluating whether this approach can produce meaningful and sustained weight reduction while also improving certain cardiometabolic markers.
Potential Benefits Observed in Clinical Research
Clinical studies have explored several possible benefits of retatrutide. It is important to note that these findings come from controlled trial settings and individual results can vary significantly.
Weight Management In published Phase 2 research, participants receiving retatrutide experienced substantial reductions in body weight over 48 weeks. The highest dose studied (12 mg) was associated with an average weight reduction of approximately 24.2%. A large proportion of participants achieved clinically meaningful weight loss thresholds (5%, 10%, and 15% or more of starting body weight).
More recent Phase 3 topline data from the TRIUMPH-1 trial (released in May 2026) showed even greater average weight reductions at longer durations. At 80 weeks, participants on the 12 mg dose lost an average of 28.3% of their starting body weight. Some participants in an extension phase reached around 30% weight loss by week 104. These levels are notable and have been compared in research discussions to outcomes sometimes seen with bariatric procedures, though direct comparisons require careful interpretation.
Cardiometabolic Improvements Beyond weight loss, trials have measured improvements in several related health markers, including:
- Reductions in waist circumference
- Improvements in lipid profiles (such as triglycerides and non-HDL cholesterol)
- Reductions in systolic blood pressure
- Lower levels of high-sensitivity C-reactive protein (hsCRP), a marker of inflammation
These secondary outcomes are still being fully analyzed across the broader Phase 3 program.
Glycemic Control Separate Phase 3 studies in adults with type 2 diabetes have also shown meaningful reductions in HbA1c alongside weight loss. This dual benefit on blood sugar and body weight is an area of active investigation.
It is essential to understand that retatrutide is not currently approved for any of these uses. All potential benefits remain under evaluation in ongoing clinical trials.
Clinical Trial Results: What the Research Shows
Phase 2 Trial (Published in NEJM, 2023) This 48-week study involved adults with obesity or overweight. Key findings included dose-dependent weight loss, with the 12 mg group showing the greatest average reduction. Gastrointestinal side effects were the most commonly reported adverse events and were generally mild to moderate.
Phase 3 TRIUMPH Program (2026 Updates) The ongoing TRIUMPH clinical trial program includes multiple large-scale studies. Topline results from TRIUMPH-1 (obesity without diabetes) demonstrated robust weight loss at 80 weeks, with a significant percentage of participants achieving 30% or greater weight reduction on the highest dose. Additional trials are evaluating retatrutide in people with type 2 diabetes and those with established cardiovascular disease.
Longer-term data and full peer-reviewed publications from the Phase 3 program are still awaited. Regulatory review typically follows completion of these studies.
Safety Profile and Side Effects
Like other medications in the GLP-1 and dual agonist class, retatrutide’s most frequently reported side effects in trials have been gastrointestinal in nature. These may include:
- Nausea
- Vomiting
- Diarrhea
- Constipation
These effects were often more common during dose escalation and tended to decrease over time for many participants. Researchers noted that starting with a lower dose and gradual titration helped reduce their severity.
Other observations in trials have included increases in heart rate (which peaked and then declined in many cases) and changes in skin sensation in a smaller percentage of participants. Long-term safety data are still being collected through the ongoing Phase 3 studies.
Because retatrutide remains investigational, its full safety profile — including rare or long-term effects — is not yet fully established. Anyone considering participation in clinical trials or future approved use should discuss risks thoroughly with a healthcare provider.
Current Status and Availability (as of June 2026)
Retatrutide is not approved for use anywhere in the world at this time. It is available only to participants enrolled in clinical trials. Eli Lilly has indicated plans to submit regulatory applications following completion of the Phase 3 program, but approval timelines remain uncertain and are typically measured in years after positive trial results.
Sourcing retatrutide from unregulated or black-market suppliers is illegal in most countries and carries serious safety risks, including potential contamination or incorrect dosing. Regulatory authorities have issued warnings about such products.
Important Considerations
- Retatrutide is still an experimental treatment. Decisions about its future use will depend on the complete results of ongoing trials and regulatory review.
- Individual responses to any medication can vary based on many factors, including overall health, other medications, and lifestyle.
- Sustainable weight management generally involves a combination of dietary changes, physical activity, behavioral support, and medical supervision when appropriate.
- People with certain medical conditions (such as a history of pancreatitis, thyroid cancer, or specific gastrointestinal disorders) may not be suitable for this class of medications.
This article is intended solely to help readers understand the current state of research on retatrutide. It does not promote or encourage the use of any unapproved medication.
Conclusion
Retatrutide represents an interesting development in the field of obesity and metabolic research due to its novel triple agonist mechanism. Early and mid-stage clinical trials have shown promising levels of weight reduction and improvements in certain cardiometabolic markers. However, it is important to remember that the medication is still investigational.
As more Phase 3 data become available and undergo peer review, the medical community will gain a clearer picture of its efficacy and safety profile. Until regulatory approval is granted, retatrutide should only be accessed through properly conducted clinical trials under medical supervision.
For the most accurate and up-to-date information, readers are encouraged to consult healthcare professionals and refer to official sources such as ClinicalTrials.gov and publications from regulatory agencies.
Sources
- Jastreboff AM, et al. Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. New England Journal of Medicine. 2023.
- Eli Lilly and Company. TRIUMPH-1 Phase 3 Trial Topline Results (May 2026).
- Additional data from Lilly investor communications and clinical trial registries (as of June 2026)